Tirzepatide vs AOD-9604 & CJC-1295 & Ipamorelin (Stack)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Tirzepatide
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.
Full details →AOD-9604 & CJC-1295 & Ipamorelin (Stack)
A targeted fat loss stack combining AOD-9604 (the fat-burning fragment of HGH) with CJC-1295 and Ipamorelin for comprehensive body recomposition. This blend addresses fat loss directly while supporting lean mass through GH optimization.
Full details →Side-by-Side Comparison
| Aspect | Tirzepatide | AOD-9604 & CJC-1295 & Ipamorelin (Stack) |
|---|---|---|
| Mechanism | Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, providing synergistic effects on insulin secretion, appetite suppression, and metabolic regulation. The dual mechanism may explain its enhanced efficacy. | AOD-9604 stimulates lipolysis and inhibits lipogenesis without affecting IGF-1 or blood glucose. CJC-1295 and Ipamorelin provide sustained and pulsatile GH release to support metabolism and lean tissue. The combination targets fat loss through multiple mechanisms while preserving muscle. |
| Typical Dosage | Start at 2.5mg weekly, titrate every 4 weeks through 5mg, 7.5mg, 10mg, 12.5mg, to maximum 15mg weekly. Full titration takes approximately 20 weeks. | Typical protocol: AOD-9604 200-400mcg, CJC-1295 100-200mcg, Ipamorelin 100-200mcg daily. Usually administered in the morning fasted or before exercise. |
| Administration | Subcutaneous injection once weekly. Rotate injection sites. Slower titration may help reduce GI side effects. | Subcutaneous injection. Best administered fasted to maximize fat-burning effects. Can be taken as a pre-mixed blend or separate injections. Cycles typically run 8-16 weeks. |
| Side Effects | Similar to semaglutide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite. Generally improve with continued use. | Mild injection site reactions, headache, nausea. Generally well-tolerated as AOD-9604 lacks many HGH side effects. |
| Best For |
What They Have in Common
Both Tirzepatide and AOD-9604 & CJC-1295 & Ipamorelin (Stack) are commonly used for: